EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adapted Live SARS‐CoV‐2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5

Jana Kochmann, Tobias Britzke, Nico Joël Halwe, Lorenz Ulrich, Angele Breithaupt, G Tuba Barut, Nadine Ebert, Bettina Salome Trüeb, Volker Thiel, Anca Dorhoi, Martin Beer, Donata Hoffmann und 2 weitere

European Journal of Immunology · 2026-05 · 56 (5)

DOI: 10.1002/eji.70196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 04.05.2026. Verfasst von Jana Kochmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Immunity, Mucosal, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RocketVax AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of SARS‐CoV‐2 variants, like XBB.1.5, causing immune evasion and frequent breakthrough infections, emphasizes the need for vaccines that limit transmission and target newly emerging variants. Mucosal vaccines, particularly live attenuated vaccines (LAV), are promising candidates for inducing strong mucosal immune responses to prevent viral replication and transmission. Vaccination with the previously described “one‐to‐stop” codon‐modified LAV OTS‐228, carrying the ancestral spike protein, induced sterilizing immunity against ancestral SARS‐CoV‐2 but also broad protection against Omicron variants, including XBB.1.5, but transmission of XBB.1.5 to contacts could not be prevented completely. As a proof‐of‐concept, we updated OTS‐228 by replacing the sequence coding for the ancestral SARS‐CoV‐2 spike protein with that of the XBB.1.5 variant. We applied flow cytometry to detect SARS‐CoV‐2‐specific T cell responses, as well as ELISA and qPCR, to characterize systemic and mucosal immune responses in Syrian hamsters in detail. The new OTS construct designated as “OTS‐300” exhibited an optimal safety profile in Syrian hamsters comparable to the original candidate vaccine. A single‐dose intranasal (i.n.) vaccination with OTS‐300 protects against disease, substantially limits XBB.1.5 replication, and reduces transmission in Syrian hamsters, showcasing the adaptability of the OTS platform for other emerging variants. OTS‐300 induced accelerated mucosal and systemic antibody responses and reduced virus‐mediated inflammation as compared with an intramuscularly delivered mRNA vaccine encoding the XBB.1.5 Spike.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Immunity, MucosalCOVID-19 VaccinesCOVID-19AnimalsVaccines, AttenuatedSpike Glycoprotein, CoronavirusAntibodies, ViralHumansVirus SheddingT-LymphocytesMesocricetusVaccinationSterilizing ImmunityAntibodies, Neutralizing

Substanzen

COVID-19 VaccinesVaccines, AttenuatedSpike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2Antibodies, Neutralizing

Autor:innen und Institutionen

  • Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
  • Institute of Virology and Immunology, Bern and Mittelhäusern, Bern, Switzerland.
  • Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland.

Förderung

  • RocketVax AG

Zitieren

APA

Kochmann, J., Britzke, T., Halwe, N. J., Ulrich, L., Breithaupt, A., Barut, G. T., Ebert, N., Trüeb, B. S., Thiel, V., Dorhoi, A., Beer, M., Hoffmann, D., Corleis, B., & Schön, J. (2026). Adapted Live SARS‐CoV‐2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5. European Journal of Immunology, 56(5). https://doi.org/10.1002/eji.70196

Vancouver

Kochmann J, Britzke T, Halwe NJ, Ulrich L, Breithaupt A, Barut GT, et al. Adapted Live SARS‐CoV‐2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5. European Journal of Immunology. 2026;56(5). doi:10.1002/eji.70196

BibTeX
@article{Kochmann2026,
  author = {Kochmann, Jana and Britzke, Tobias and Halwe, Nico Joël and Ulrich, Lorenz and Breithaupt, Angele and Barut, G Tuba and Ebert, Nadine and Trüeb, Bettina Salome and Thiel, Volker and Dorhoi, Anca and Beer, Martin and Hoffmann, Donata and Corleis, Björn and Schön, Jacob},
  title = {Adapted Live SARS‐CoV‐2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5},
  journal = {European Journal of Immunology},
  year = {2026},
  volume = {56},
  number = {5},
  doi = {10.1002/eji.70196}
}
Kostenlos starten →